why choose us

First received: April 17, 2024

Clinical Trial: Clinical Evaluation of 177Lu-DansyI-PSMA (LNC1011) in Patients With Metastatic Castration-Resistant Prostate Cancer

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Metastatic Castration-resistant Prostate Cancer, mCRPC

Study Type: INTERVENTIONAL


Official Title: An Open-Label, Non-Randomized, Single-Center, Investigator-Initiated Trial to Determine the Safety, Dosimetry, and Preliminary Effectiveness of 177Lu-Dansyl-PSMA in Patients With Metastatic Castration

Brief Summary: Ten to 20% of patients with prostate cancer (PC) experience progression in their disease, even after undergoing pharmaceutical or surgical castration, leading to metastatic CRPC (mCRPC).Prostate-specific membrane antigen (PSMA) is a membrane-bound glycoprotein mostly specific to the prostate.While PSMA is expressed at low levels in normal prostate, this expression increased by 100-1000-fold in PC, which makes it a favorable target for therapy.This study was designed to evaluate the safety, tolerability, and…

Read more